Advanced searches left 3/3

Metronidazole - DOAJ

Summarized by Plex Scholar
Last Updated: 23 April 2022

* If you want to update the article please login/register

Fabrication and In Vitro/In Vivo Appraisal of Metronidazole Intra-Gastric Buoyant Sustained-Release Tablets in Healthy Volunteers

Helicobacter pylori is thought to be the most common cause of peptic and duodenal ulcers. According to our goal, we wanted to produce and evaluate sustained release floating tablets for metronidazole to extend the gastric residence period and monitor the release rate of metronidazole. According to the Hichi method, metronidazole release from the floating tablets was significantly lower than that from conventional tablets, indicating sustained drug release. After a single oral dose of 150 mg metronidazole as floating tablets, a new bioavailability study in healthy volunteers revealed significant increased bioavailability, increased Tmax, AUC, and MRT; and a significantly reduced absorption rate constant. In addition, the significant rise in MRT suggested an in-vivo sustained drug release. In conclusion, the tablets may be promising for increasing both local and systemic metronidazole Efficacy.

Source link: https://doi.org/10.3390/pharmaceutics14040863


Amoxicillin/Metronidazole Dose Impact as an Adjunctive Therapy for Stage II - III Grade C Periodontitis (Aggressive Periodontitis) at 3- And 6-Month Follow-Ups: a Systematic Review and Meta-Analysis

After the latest follow-up, this systematic review and meta-analysis effort sought to determine the amoxicillin/metronidazole dose and duration time in the treatment of stage II - III grade C periodontitis. At 3 and 6 months of follow-up, the weighted mean difference and 95% confidence interval of clinical attachment level increase and probing depth decrease were calculated. Even in modest pockets, Prescriptions of 400 to 500 mg metronidazole resulted in significant CAL gain changes. Amoxicillin/metronidazole has positive short-term results as an adjunct to scaling and root planning for treatment of stage II - III grade C periodontitis.

Source link: https://doi.org/10.5037/jomr.2022.13102


Bioadhesive Controlled Metronidazole Release Matrix Based on Chitosan and Xanthan Gum

This binary chitosan-xanthan gum mixture's hydrogel structure was evaluated for its ability to monitor metronidazole's release as a drug model. In 0. 1 M HCl and phosphate buffer pH 6. 8, the in vitro drug-release profiles of metronidazole preparation and CMZ were similar. Furthermore, metronidazole preparation and CMZ showed a similar detachment factor to sheep stomach mucosa, although the metronidazole preparation was more effective three times than CMZ to sheep duodenum. The results of an in vitro review indicated that metronidazole absorption from the preparation was quicker than that of CMZ. As a result of the development of the chitosan-xanthan gum mixture as a hydrophilic polymer matrix, better pharmacokinetic parameters were obtained, as a result of increased rate and extent of metronidazole absorption.

Source link: https://doi.org/10.3390/md8051716


Formulation of metronidazole tablets containing hydroxypropylated white yam (Dioscorea rotundata) starch as binding agent

In comparison to corn starch BP, the white yam starch obtained from Dioscorea rotundata Poir tubers was modified by hydroxypropylation and used as a binding agent in Metronidazole tablet formulation. Using a complete 23 factorial experimental research approach, the novel starch binder's quantitative effects on the metronidazole tablet's mechanical and release characteristics have been investigated. Hydroxypropyl white yam starch white yam starch may be more effective as a binder, particularly when tablets have a mechanical strength but faster drug delivery characteristics are needed.

Source link: https://doaj.org/article/be2a2c15ccc0421eadf10a0e63d30c8b


Metronidazole; a Potential Novel Addition to the COVID-19 Treatment Regimen

Metronidazole has been shown to reduce the levels of several cytokines, which are known to rise during COVID-19 disease, including interleukin 8, IL6, tumor necrosis factor Î3, and interferon Î 3, as well as the levels of C-reactive protein and neutrophil count, which are known to rise during COVID-19 infection, as well as in vitro and in vivo studies. Metronidazole could be able to treat the overwhelming number of the COVID-19 disease's immunopathological manifestations. To establish the effectiveness of metronidazole in the treatment of COVID-19 infection, we need research with a large sample size.

Source link: https://doi.org/10.22037/aaem.v8i1.645


One year results of a randomized controlled clinical study evaluating the effects of non-surgical periodontal therapy of chronic periodontitis in conjunction with three or seven days systemic administration of amoxicillin/metronidazole.

Patients with severe chronic periodontitis et alphatic debridement were treated randomly for 12 months, and amoxicillin and metronidazole adjunctive therapies were administered in patients with severe chronic periodontitis. 102 patients with sChP were treated randomly as follows: SD+AMX+MET for 7 days, a placebo for 7 days. Mean residual PD were statistically significant lower and CAL gain was statistically significant higher in the two antibiotic groups, relative to placebo. Although PD declines and CAL gains were statistically significant in group C relative to group A, only the 3-day AB group had statistically significantly less sites with PD6mm at 12 m compared to group A. Both adjunctive antibiotic regimens resulted in statistically significant improvement in both antibiotic groups at 12 months compared to placebo, with significantly higher incidence of disease progression in both antibiotic groups at 12 months.

Source link: https://doi.org/10.1371/journal.pone.0179592


Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the United States

Abstract Background The prevalence of antimicrobial resistance among gram-negative pathogens in complicated intra-abdominal infections has increased. ceftolobactam + metronidazole, a cost-effectiveness study conducted in the treatment of hospitalized U. S. patients with cIAI who are susceptible to infection with resistant pathogens in the treatment of hospitalized U. S. patients with cIAI are susceptible to infection with resistant pathogens. Methods We used a decision-analytic Monte Carlo simulation to compare the costs and quality-adjusted life years of people with nosocomial gram-negative cIAI treated empirically with either ceftolozane/tazobactam + metronidazole or piperacillin/tazobactam. Patients with cIAIs in medical centers in the United States were randomly drawn from the Program to Assess Ceftolobactam Susceptibility database, a surveillance database of non-duplicate bacterial isolates collected from patients with cIAIs in medical centers in the United States from 2011 to 2013. Conclusions Our model results, as well as baseline resistance values from the PACTS database, showed that ceftolobactam + metronidazole dominated piperacillin/tazobactam, with lower prices and higher QALYs compared to baseline controls.

Source link: https://doi.org/10.1186/s13756-017-0264-2


The effect of metronidazole plus amoxicillin or metronidazole plus penicillin V on a periodontal biofilm model. An in vitro study.

In the case of metronidazole, the aim of this research was to determine the effect of replacing broad-spectrum amoxicillin with penicillin V in the combination with metronidazole. Both antibiotic regiments were safe against F. nucleatum and P. gingivalis, but not so effective against A. actinomycetemcomitans. A. actinomycetemcomitans [in both high and low concentrations] were not present in either of the two formulations of antibiotics to combat A. actinomycetemcomitans. Conclusion: On an in vitro three-species biofilm model, a combination of metronidazole with penicillin V had similar inhibiting activity as metronidazole mixed with amoxicillin.

Source link: https://doi.org/10.1080/20002297.2017.1325270


Comparison of oral and vaginal metronidazole for treatment of bacterial vaginosis in pregnancy: impact on fastidious bacteria

BACterial vaginosis is a common condition that is associated with preterm birth and the development of numerous species of vaginal bacteria that include many fastidious species. BV treatment in pregnancy has mixed results on the risk of premature birth, with some hypothesizes owing to variations in antibiotic efficacy for the fastidious bacteria. Both oral and intravaginal metronidazole can be used to treat bacterial vaginosis in pregnancy, but no information is available about the effects of different routes of antibiotic delivery on concentrations of fastidious vaginal bacteria. Conclusion Both oral and vaginal metronidazole therapy in pregnant women results in a significant decrease in blood concentrations of most BV-associated anaerobic bacteria, with the exception that Leptotrichia, Sneathia, and BVAB1 did not significantly reduce with vaginal metronidazole therapy. These findings reveal that antibiotic therapy has no effect on bacterial eradication in pregnant women with BV.

Source link: https://doi.org/10.1186/1471-2334-9-89


A case of methylprednisolone treatment for metronidazole-induced encephalopathy

Case report After taking metronidazole at the dose of about 32 g for 20 days, a 57-year-old man was admitted to our hospital due to dysarthria and ataxic gait. In T2W and FLAIR photographs, the brain magnetic resonance imaging revealed hyper-intensities in the bilateral cerebellar dentate nuclei, medulla oblongata, midbrain, and red nuclei. Conclusions In our case, we show that early methylprednisolone therapy could delay metronidazole-induced encephalopathy formation and stimulate neurological recovery. We infer that the development of encephalopathy is due to the delayed toxicity attributed to high doses or concentrations of metronidazole.

Source link: https://doi.org/10.1186/s12883-019-1278-6

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions